Prevention of Recurrent C. Difficile Infection Study With AZD5148 Monoclonal Antibody
← catalyst calendarNCT07285213 · readout in 244 d
Sponsored by AstraZeneca (industry) · AZN — their whole pipeline →.
Phase
Phase 2
Status
Recruiting
Study type
Interventional
Design
Randomized · Quadruple · Prevention
Enrollment
230estimated
Sites
116
Countries
Australia, Canada, Denmark +11
Every value on this page is a field the sponsor filed with ClinicalTrials.gov, reproduced. Dates are their own estimates, revised as a study runs, unless the registry marks them actual. sources →
Source: ClinicalTrials.gov, retrieved 2026-08-19
Dates
each axis at the precision it was filed, with the registry's own basis| Date | Filed | Basis | What it is |
|---|---|---|---|
| Start | 2025-12-10 | actual | When the study began enrolling |
| Primary completion | 2027-04-20 | estimated | The date the last participant is measured for the primary outcome — the readout window |
| Study completion | 2028-01-18 | estimated | The whole study's end, after follow-up |
| First posted | 2025-12-16 | actual | When this record first appeared on the registry |
| Results posted | — | When the sponsor posted results to the registry | |
| Record updated | 2026-08-12 | actual | The sponsor's own last edit to this record — every projection above is as current as this date |
What it studies
Condition
- Clostridioides Difficile Infection
Interventions
- Drug: AZD5148
- Other: Placebo
Primary outcome
what the primary-completion date above is the date OFFirst occurrence of recurrence of C difficile infection
measured Day 1 through day 91
Permalink · AZN's whole pipeline · Catalyst calendar · Every registered study · What changed